318 related articles for article (PubMed ID: 8790196)
21. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury.
Ogawa T; Kanno I; Shishido F; Inugami A; Higano S; Fujita H; Murakami M; Uemura K; Yasui N; Mineura K
Acta Radiol; 1991 May; 32(3):197-202. PubMed ID: 2064862
[TBL] [Abstract][Full Text] [Related]
22. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.
Weber W; Bartenstein P; Gross MW; Kinzel D; Daschner H; Feldmann HJ; Reidel G; Ziegler SI; Lumenta C; Molls M; Schwaiger M
J Nucl Med; 1997 May; 38(5):802-8. PubMed ID: 9170450
[TBL] [Abstract][Full Text] [Related]
23. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
Yamamoto Y; Kawaguchi Y; Kawase Y; Maeda Y; Nishiyama Y
Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
[TBL] [Abstract][Full Text] [Related]
24. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
[TBL] [Abstract][Full Text] [Related]
25. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine.
Reinhardt MJ; Kubota K; Yamada S; Iwata R; Yaegashi H
J Nucl Med; 1997 Feb; 38(2):280-7. PubMed ID: 9025756
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive grading of musculoskeletal tumors using PET.
Adler LP; Blair HF; Makley JT; Williams RP; Joyce MJ; Leisure G; al-Kaisi N; Miraldi F
J Nucl Med; 1991 Aug; 32(8):1508-12. PubMed ID: 1869970
[TBL] [Abstract][Full Text] [Related]
27. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET.
Kim EE; Chung SK; Haynie TP; Kim CG; Cho BJ; Podoloff DA; Tilbury RS; Yang DJ; Yung WK; Moser RP
Radiographics; 1992 Mar; 12(2):269-79. PubMed ID: 1561416
[TBL] [Abstract][Full Text] [Related]
28. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
29. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung.
Sasaki M; Kuwabara Y; Yoshida T; Nakagawa M; Koga H; Hayashi K; Kaneko K; Chen T; Ichiya Y; Masuda K
Ann Nucl Med; 2001 Oct; 15(5):425-31. PubMed ID: 11758947
[TBL] [Abstract][Full Text] [Related]
30. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.
Torizuka T; Tamaki N; Inokuma T; Magata Y; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J
J Nucl Med; 1994 Dec; 35(12):1965-9. PubMed ID: 7989978
[TBL] [Abstract][Full Text] [Related]
31. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
[TBL] [Abstract][Full Text] [Related]
32. [Diagnosis of early cancer with positron emission tomography].
Kubota K
Nihon Rinsho; 1996 May; 54(5):1263-7. PubMed ID: 8965348
[TBL] [Abstract][Full Text] [Related]
33. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
34. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography.
Utriainen M; Metsähonkala L; Salmi TT; Utriainen T; Kalimo H; Pihko H; Mäkipernaa A; Harila-Saari A; Jyrkkiö S; Laine J; Någren K; Minn H
Cancer; 2002 Sep; 95(6):1376-86. PubMed ID: 12216107
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer.
Yoshioka T; Yamaguchi K; Kubota K; Saginoya T; Yamazaki T; Ido T; Yamaura G; Takahashi H; Fukuda H; Kanamaru R
J Nucl Med; 2003 May; 44(5):690-9. PubMed ID: 12732669
[TBL] [Abstract][Full Text] [Related]
36. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG.
Kubota R; Kubota K; Yamada S; Tada M; Takahashi T; Iwata R; Tamahashi N
J Nucl Med; 1995 Mar; 36(3):484-92. PubMed ID: 7884515
[TBL] [Abstract][Full Text] [Related]
37. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study.
Leskinen-Kallio S; Ruotsalainen U; Någren K; Teräs M; Joensuu H
J Nucl Med; 1991 Jun; 32(6):1211-8. PubMed ID: 2045935
[TBL] [Abstract][Full Text] [Related]
38. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography.
Yanagawa T; Watanabe H; Inoue T; Ahmed AR; Tomiyoshi K; Shinozaki T; Oriuchi N; Endo K; Takagishi K
J Comput Assist Tomogr; 2003; 27(2):175-82. PubMed ID: 12703009
[TBL] [Abstract][Full Text] [Related]
39. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.
Zasadny KR; Wahl RL
Radiology; 1993 Dec; 189(3):847-50. PubMed ID: 8234714
[TBL] [Abstract][Full Text] [Related]
40. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
